Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck
Despite recent advances in novel therapies, the prognosis for patients with squamous cell
carcinoma of the head and neck (SCCHN) remains poor. Progress in understanding the …
carcinoma of the head and neck (SCCHN) remains poor. Progress in understanding the …
The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination …
N Akbari Dilmaghani, A Safaroghli‐Azar… - IUBMB …, 2021 - Wiley Online Library
The latest advances in the sequencing methods in head and neck squamous cell carcinoma
(HNSCC) tissues have revolutionized our understanding of the disease by taking off the veil …
(HNSCC) tissues have revolutionized our understanding of the disease by taking off the veil …
EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy
C Freudlsperger, JR Burnett, JA Friedman… - Expert opinion on …, 2011 - Taylor & Francis
Importance of the field: Recent advances in the understanding of the oncogenesis of head
and neck squamous cell carcinomas (HNSCC) have revealed multiple dysregulated …
and neck squamous cell carcinomas (HNSCC) have revealed multiple dysregulated …
Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC
AD Swick, PJ Prabakaran, MC Miller, AM Javaid… - Molecular cancer …, 2017 - AACR
Head and neck squamous cell carcinomas (HNSCC) are frequently altered along the
PI3K/AKT/mTORC signaling axis. Despite excellent preclinical data, the use of compounds …
PI3K/AKT/mTORC signaling axis. Despite excellent preclinical data, the use of compounds …
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)
K Jung, H Kang, R Mehra - Cancers of the head & neck, 2018 - Springer
The landscape of head and neck squamous cell carcinoma (HNSCC) has been changing
rapidly due to growing proportion of HPV-related disease and development of new …
rapidly due to growing proportion of HPV-related disease and development of new …
[HTML][HTML] Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma
Y Cai, S Dodhia, GH Su - Oncotarget, 2017 - ncbi.nlm.nih.gov
Abstract The phosphoinositide 3-kinase (PI3K) signaling pathway is the most commonly
mutated pathway in head and neck squamous cell carcinoma (HNSCC). There are several …
mutated pathway in head and neck squamous cell carcinoma (HNSCC). There are several …
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic …
Introduction The phosphotidylinositol-3 kinase (PI3K)/serine–threonine kinase
(AKT)/mammalian target of rapamycin (mTOR) signaling pathway is frequently altered in …
(AKT)/mammalian target of rapamycin (mTOR) signaling pathway is frequently altered in …
Targeting the PI3K pathway in head and neck squamous cell carcinoma
PH Isaacsson Velho, G Castro Jr… - American Society of …, 2015 - ascopubs.org
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease arising
from the mucosal epithelia in the head and neck region. The most common risk factors are …
from the mucosal epithelia in the head and neck region. The most common risk factors are …
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer
FE Marquard, M Jücker - Biochemical pharmacology, 2020 - Elsevier
The aim of this review is to summarize current available information about the role of
PI3K/AKT/mTOR signaling in head and neck cancer as a potential target for new therapy …
PI3K/AKT/mTOR signaling in head and neck cancer as a potential target for new therapy …
[HTML][HTML] A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or …
A Jimeno, K Shirai, M Choi, J Laskin, M Kochenderfer… - Annals of oncology, 2015 - Elsevier
This manuscript reports on a prospective, randomized study of cetuximab plus/minus a small
molecule PI3K inhibitor (PX-866) targeting the protein product of PIK3CA, the gene with the …
molecule PI3K inhibitor (PX-866) targeting the protein product of PIK3CA, the gene with the …